Shopping Cart
Remove All
Your shopping cart is currently empty
CCR6 antagonist 1, a chemical compound acting as a CCR6 antagonist, effectively inhibits the CCL20/CCR6 axis. Its utility lies in research focused on autoimmune-mediated inflammatory diseases, including inflammatory bowel diseases (IBDs).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $31 | - | In Stock | |
| 2 mg | $44 | - | In Stock | |
| 5 mg | $72 | - | In Stock | |
| 10 mg | $113 | - | In Stock | |
| 25 mg | $239 | - | In Stock | |
| 50 mg | $347 | - | In Stock | |
| 100 mg | $537 | - | In Stock | |
| 200 mg | $759 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $79 | - | In Stock |
| Description | CCR6 antagonist 1, a chemical compound acting as a CCR6 antagonist, effectively inhibits the CCL20/CCR6 axis. Its utility lies in research focused on autoimmune-mediated inflammatory diseases, including inflammatory bowel diseases (IBDs). |
| In vitro | CCR6 antagonist 1 (50 μM, 3 h) blocks the CCL20-induced CD4+ T cell migration. CCR6 antagonist 1 (30 nM-300 μM, 20 min) inhibits miniGi recruitment to CCR6 induced by CCL20, and β-arrestin-1 recruitment to CCR6 and CCR5 by CCL20 and CCL5 (5 nM), respectively[1]. |
| In vivo | CCR6 antagonist 1 (1 mg/kg, s.c., twice daily for 3 days) alleviates TNBS-induced inflammatory responses in mice. CCR6 antagonist 1 (1 mg/kg, s.c., twice, before and after zymosan treatment) shows anti-inflammatory effects in Zymosan-induced peritonitis mice[1]. |
| Molecular Weight | 319.28 |
| Formula | C17H12F3NO2 |
| Cas No. | 588674-64-0 |
| Smiles | Cc1c(oc2ccccc12)C(=O)Nc1ccc(cc1)C(F)(F)F |
| Relative Density. | 1.358 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (281.88 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 1 mg/mL (3.13 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.